About

Team Leader

Prof. Rajiv Jalan (MD, PhD)

Hepatology Professor

Phone: +44 207 433 279 5

Send message

Team Members

Jane Macnaughtan (PhD)

Co-Principal Investigator

Phone: +44 207 433 287 4

Send message

Qianwen Zhao

PhD student

Phone: +44 075 299 506 43

Send message

Institute Presentation

University College London (UCL) has a global reputation for excellence in research and is committed to delivering impact and is currently 8th in the QS World University Rankings. UCL was the top performing university in the first year of Horizon 2020 and 7th institution overall in EU collaborative research (#3 in the UK). The Liver Failure Group at UCL has been the recipient of two major EU Horizon 2020 grants led by Professor Rajiv Jalan to modulate bacterial translocation in advanced liver disease.

Professor Rajiv Jalan, is a Professor of Hepatology at UCL and head of the Liver Failure Group. His main interest is in understanding the pathophysiology of liver failure and he first recognised the syndrome now referred to as acute-on-chronic liver failure. His research has led to the publication of over 200 papers and to 9 patentable inventions. He has extensive experience of running large translational programmes targeting bacterial translocation and Toll-Like Receptor 4 pathways. Rajiv is Editor-in-Chief of the Journal of Hepatology, founder member of the EASL-CLIF Consortium and Coordinator of 2 EU Horizon 2020 grants ALIVER and CARBALIVE.

Dr. Jane MacNaughtan, is a Senior Lecturer in Hepatology and has extensive experience in studying the gut-liver axis in liver failure. Her research with Yaq-001 in preclinical models of cirrhosis and non-alcoholic steatohepatitis constituted the proof of concept data for the successful Horizon 2020 CARBALIVE program. She is actively involved the subsequent translational work and is leading on delivering the CARBALIVE grant.

Within MICROB-PREDICT, UCL is involved in selection and collection of control samples (WP1) and validation of in vitro findings in experimental cirrhosis in analbuminic rats treated with albumin (WP6). They will be a centre for the interventional clinical study (WP7) and involved in dissemination activity for scientists and medical community.